SYS ONLINE
SUPPLEMENT_SCHOLAR
evidence · mechanism · dose
Experimental/Metabolic / GLP-1Research peptide

Semaglutide

aka Ozempic · Wegovy · Rybelsus

Long-acting GLP-1 receptor agonist used for weight loss and glycemic control.

Educational explainer of a research peptide. Profiles in this section deliberately omit clinical-trial citations, dosing protocols, and purchase links. Not FDA-approved as a supplement; not a recommendation to use.

Overview

Semaglutide is a modified GLP-1 analog with a fatty-acid side chain that binds albumin, extending its half-life to roughly a week.

Source
  • Recombinant expression
Forms
  • Once-weekly subcutaneous injection
  • Daily oral tablet

Mechanism of action

Activates GLP-1 receptors in pancreas, brain, and gut, increasing glucose-dependent insulin secretion, slowing gastric emptying, and reducing appetite.

Pathways
  • · GLP-1 receptor agonism
  • · POMC / NPY hypothalamic balance
Receptors
  • · GLP-1 receptor
Hormones
  • · Insulin
  • · Glucagon

How it acts on the body

Semaglutide hits GLP-1 receptors that are distributed widely beyond the pancreas — including hypothalamic appetite circuits, the area postrema, and gastric smooth muscle. The combined effect is glucose-dependent insulin release plus a strong reduction in hunger and a slowing of stomach emptying, which together drive sustained weight loss.

Because hunger reduction is centrally mediated rather than caloric-trick mediated, the weight loss tends to include lean mass alongside fat. The slowed gastric emptying is also the basis for the most common side effects (nausea, reflux) and for anesthesia-related warnings about residual gastric content.

Hormonal & endocrine impact

How this peptide is reported to shift specific hormones and signaling molecules. Directionality reflects research literature and preclinical models, not clinical prescribing data.

Projected hormonal trajectory
Illustrative curves derived from reported direction of effect. Not measured patient data.

Curves are schematic shapes (sigmoid for increases/decreases, damped oscillation for modulation/stabilization) anchored to a 100% baseline. They communicate direction and tempo of change reported in research literature — not absolute hormone concentrations.

InsulinIncreases
Glucose-dependent secretion from pancreatic beta cells.
GlucagonDecreases
Postprandial glucagon suppression lowers hepatic glucose output.
GhrelinDecreases
Indirectly reduced via slower gastric emptying and central hunger reduction.
Leptin sensitivityModulates
Improves with weight loss and hypothalamic signaling shifts.

Effects on the body

Decreases
Appetite and food intake
Increases
Glucose-dependent insulin secretion
Decreases
Body weight

Organ system effects

Endocrine

Glucose-dependent insulin/glucagon balance.

Brain & CNS

Centrally reduced hunger via hypothalamus and brainstem.

Digestive / Gut

Slowed gastric emptying and altered satiety signaling.

Reported effects

Drawn from preclinical research, anecdote, and small-scale clinical observation. No evidence grades are assigned — most peptides on this page lack rigorous human trials.

  • Robust weight loss
  • Improved A1c and cardiovascular outcomes
  • Reduced food noise

Potential side effects

Common
  • · Nausea
  • · Reflux
  • · Constipation
  • · Fatigue
Rare
  • · Gallstones
  • · Injection-site reactions
Serious
  • · Pancreatitis (rare)
  • · Possible thyroid C-cell tumor risk (rodent data)

Drug interactions

Sulfonylureas or insulin
Hypoglycemia risk; dose adjustment expected.
moderate

Pairing context

Often combined with
  • Resistance training and adequate protein
    Protects lean mass during weight loss.
Avoid combining with
  • Personal or family history of MTC or MEN2
    Boxed contraindication.
Important. Research peptides described here are not FDA-approved supplements. Supplement Scholar does not endorse, recommend, or link to any source for purchase. Consult a qualified clinician before considering any peptide therapy.